All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...

Please provide your email address to receive an email when new articles are posted on . The treatment is approved for heavily pretreated patients. Researchers reported an objective response rate of 70 ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

Lynozyfic showed a 79% overall response rate in newly diagnosed multiple myeloma, with 86% in the 200 mg dose group. Rapid responses were observed, with a median time to partial response of 1.2 months ...

TARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for adults with relapsed and refractory multiple myeloma. This approval ...

Regeneron Pharmaceuticals has won Food and Drug Administration accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma. Regeneron on Wednesday said ...

“Onco360 is grateful for the opportunity to partner with the Regeneron team and become a specialty pharmacy provider for Lynozyfic,” said Benito Fernandez, Chief Commercial Officer. “We are proud to ...

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer Approval based on pivotal Phase 1/2 LINKER-MM1 trial ...